Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Portola Pharmaceuticals revenue
Portola Pharmaceuticals's revenue is $116.6 million.
What is Portola Pharmaceuticals's revenue?
- Portola Pharmaceuticals has 324 employees, and the revenue per employee ratio is $359,877.
- Portola Pharmaceuticals peak revenue was $116.6M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Portola Pharmaceuticals financing
Portola Pharmaceuticals received early financing of $21.0M on 2003-12-10.
| Series | Round size | Date |
|---|---|---|
| Series A | $21M | 12/2003 |
| Series B | $46M | 11/2005 |
| Series C | $70M | 05/2007 |
| Series C | $60M | 07/2008 |
| Corporate Round | $45M | 10/2011 |
| Series D | $89M | 11/2011 |
| Post Ipo Equity | $100M | 03/2015 |
| Post Ipo Equity | $150M | 12/2015 |
| Post Ipo Equity | $349.3M | 09/2017 |
| Post Ipo Debt | $125M | 03/2019 |
| Post Ipo Equity | $258.8M | 08/2019 |
Portola Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Sutter Hill Ventures | Series A |
| Abingworth | Series A |
| MPM Capital | Series A |
| Prospect Venture Partners | Series A |
| Frazier Healthcare Partners | Series A |
| Sutter Hill Ventures | Series B |
| Abingworth | Series B |
| MPM Capital | Series B |
| Frazier Healthcare Partners | Series B |
| Prospect Venture Partners | Series B |
| Advanced Technology Ventures | Series B |
| Alta Partners | Series B |
| The Goldman Sachs Group, Inc. | Series C |
| Sutter Hill Ventures | Series C |
| Abingworth | Series C |
| CIDC Consultants | Series C |
| MPM Capital | Series C |
| IBT Management Corporation | Series C |
| ALLIANCEBERNSTEIN L.P. | Series C |
| Alta Partners | Series C |
| Advanced Technology Ventures | Series C |
| Prospect Capital Corporation | Series C |
| Brookside Capital Inc | Series C |
| Ontario Teachers Pension Plan | Series C |
| Frazier Healthcare Partners | Series C |
| T. Rowe Price Group, Inc. | Series C |
| The Goldman Sachs Group, Inc. | Series C |
| Sutter Hill Ventures | Series C |
| APOTHECARY CAPITAL LLC | Series C |
| Abingworth | Series C |
| IBT Management Corporation | Series C |
| MPM Capital | Series C |
| Adage Capital Management | Series C |
| Advanced Technology Ventures | Series C |
| ALLIANCEBERNSTEIN L.P. | Series C |
| Alta Partners | Series C |
| Pac Link | Series C |
| D.E. Shaw & Co. | Series C |
| Janus Capital Group Inc. | Series C |
| Brookside Capital Inc | Series C |
| Frazier Healthcare Partners | Series C |
| Prospect Venture Partners | Series C |
| T. Rowe Price Group, Inc. | Series C |
| Biogen Inc. | Corporate Round |
| Eastern Capital | Series D |
| Temasek | Series D |
| Athyrium Capital Management LP | Post Ipo Debt |
| HealthCare Royalty Partners | Post Ipo Debt |
Portola Pharmaceuticals competitors
Portola Pharmaceuticals's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Portola Pharmaceuticals's smallest competitor is DURECT with revenue of $2.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 284 |
| Nektar Therapeutics | $83,561 | $98.4M | 718 | - |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Regeneron | $85,589 | $14.2B | 9,123 | 324 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 737 |
| Hospira | $64,435 | $4.5B | 19,000 | - |
| Forest Laboratories | $91,901 | $3.6B | 6,200 | - |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,601 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Boehringer Ingelheim | $106,981 | $17.2B | 52,391 | 386 |
Portola Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Portola Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Portola Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Portola Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Portola Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Portola Pharmaceuticals. The data presented on this page does not represent the view of Portola Pharmaceuticals and its employees or that of Zippia.
Portola Pharmaceuticals may also be known as or be related to PORTOLA PHARMACEUTICALS INC, Portola Pharmaceuticals, Portola Pharmaceuticals Inc and Portola Pharmaceuticals, Inc.